PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1514975
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1514975
Sulphonamides Market size was valued at USD 129.40 Million in 2023, expanding at a CAGR of 4.50% from 2024 to 2032.
Sulphonamides, also known as sulfonamides, are a class of synthetic antimicrobial agents that work by inhibiting bacterial growth. Sulphonamides is used to treat a range of infections, including urinary tract infections, respiratory tract infections, bacterial meningitis, and some sexually transmitted infections. They are also sometimes used in combination with other antibiotics for synergistic effects.
Sulphonamides Market- Market Dynamics
Growing prevalence of infection, chronic diseases and high demand for combinational therapies are expected to propel market demand
As infectious diseases continue to pose significant global health challenges, the demand for effective antibiotics like sulphonamides is rising significantly. The rise in bacterial infections such as urinary tract infections, respiratory infections, and sexually transmitted diseases drives the need for antibiotics, including sulphonamides. Sulphonamides are also used in the treatment of chronic conditions such as rheumatoid arthritis (e.g., sulfasalazine) and inflammatory bowel disease. The prevalence of these conditions drives ongoing demand for medications containing sulphonamide components.
Sulphonamides are often used in combination with other antibiotics like trimethoprim e.g., co-trimoxazole to enhance efficacy and combat resistance. The development and use of such combination therapies contribute to the demand for sulphonamides in clinical practice. Sulphonamides are more affordable compared to newer antibiotics. This cost-effectiveness is particularly important in healthcare systems with limited resources, where these antibiotics can still provide effective treatment options. These factors are expected to bolster market growth.
Sulphonamides Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.50% over the forecast period (2024-2032)
Based on Route of Administration segmentation, the oral segment was predicted to show maximum market share in the year 2023, owing to the recent COVID-19 crisis & cure.
Based on Application segmentation, the urinary tract infection (UTI) segment was the leading Application in 2023, owing to rising bacterial infection that causes mortality also.
Based on End User segmentation, the hospital segment was the leading End User in 2023, owing to the high need for treatment of urinary, diabetic, and other chronic disorders.
On the basis of region, North America was the leading revenue generator in 2023, owing to high prevalence of chronic diseases.
The Global Sulphonamides Market is segmented on the basis of Route of Administration, Application, End User, and Region.
The market is divided into three categories based on the Route of Administration: oral, topical, and others. The oral segment dominates the market. The high demand for antibiotics and infectious disease treatment is supplementing the market growth.
The market is divided into five categories based on the Application: skin infection, urinary tract infection (UTI), respiratory tract infection (RTI), gastrointestinal tract (GIT), and others. The PCR-based method segment dominates the market. Rising urinary-related diseases and new research in UTIs is contributing to segment demand.
The market is divided into three categories based on End Users: hospitals, clinics, and others. The hospital segment dominates the market and is expected to maintain its high dominance during the forecast period. The advancement in technologies and treatment of skin, and kidney transmitted disorders are mainly boosting the market growth.
Sulphonamides Market- Geographical Insights
Worldwide, the Sulphonamides market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Developed regions with robust healthcare systems, such as North America, Western Europe, and parts of Asia-Pacific including Japan, Australia, etc. often have higher consumption of sulphonamides. This is due to better access to healthcare facilities. Countries in Latin America, Eastern Europe, Asia-Pacific (e.g., India, China), and Africa are experiencing increasing healthcare expenditure and improving healthcare infrastructure.
The Sulphonamides market is moderately competitive. Companies adapt their strategies to local market conditions, regulatory environments, and healthcare systems. Established players often have a global presence with distribution networks spanning multiple countries. Advances in manufacturing processes and technologies play a significant role in competitive positioning. Companies that adopt and integrate new technologies for production or formulation enhancement can improve efficiency and product quality. Further, competing companies invest heavily in R&D to develop new formulations, improve efficacy, and reduce the side effects of sulphonamide drugs. This ongoing research drives innovation and differentiation in the market.
In August 2022, Valeo Pharma Inc. formed a supply and commercialization agreement with Novartis Pharmaceuticals in Canada for the commercialization of SIMBRINZA.
In July 2022, Azurity Pharmaceuticals Inc. established endorsement from the US FDA for ZONISADE.